By Laboratory on 1st February 2021
Biosensors Lab receives funding from HFRI under the 4th call for “Interventions to address the economic and social consequences of the COVID-19 pandemic”.
Biosensors Lab received funding to develop a rapid diagnostic tool for COVID-19 antibodies detection directly in patients samples. The project, which has a duration of 12 months, will be carried out in collaboration with clinical partners at the Univ. of Crete.
The Human Frontier Science Program posts our recent publication on “Hybrid Sensor Device for Simultaneous Surface Plasmon Resonance and Surface Acoustic Wave Measurements” that appeared in Sensors 2020, Vol 20, pp. 6177, in the HFSP News and Events.
By Laboratory on 1st December 2020
Prof. Electra Gizeli interviewed at “Kathimetini” about the rapid COVID-19 test developed in Biosensors’ lab (check News menu for more).
Prof. Electra Gizeli talks to Y. Elafros at “Kathimetini” for the novel device and rapid molecular test developed in Biosensors’ lab for COVID-19 and for applications at the point-of-care.
By Laboratory on 30th October 2020
Hybrid Sensor Device for Simultaneous Surface Plasmon Resonance and Surface Acoustic Wave Measurements by Samarentsis et al has just been published.
“Hybrid Sensor Device for Simultaneous Surface Plasmon Resonance and Surface Acoustic Wave Measurements” published on Sensors
By Laboratory on 17th October 2020
Prof. Gizeli delivered an invited talk at the 18th National congress of the Greek society of clinical chemistry-biochemistry entitled “A novel molecular diagnostic point-of-care test for SARS-CoV-2.
By Laboratory on 14th October 2020
The lab’s portable molecular diagnostic device ready to be commercially available for the detection of SARS-CoV-2 in the next few months, from FORTH’s spin off company BioPix-T.
The lab’s portable molecular diagnostic device is ready for commercial release in the next few months for the detection of SARS-CoV-2. An article in the Business section of the Greek newspaper Kathimerini is devoted on the new methodology and FORTH’s spin off company BioPix-T which has undertaken the commercial exploitation.